Overview

A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

Status:
Completed

Trial end date:
2019-08-31

Target enrollment:
0

Participant gender:
All

Summary

We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based regimens as primary therapies in eradicating H. pylori.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Shandong University

Treatments:

Bismuth
Clarithromycin
Furazolidone

Criteria

Inclusion Criteria:

- Patients, aged between 18 and 75years old, with positive H. pylori infection that was
not eradicated by previous therapies are included. The H. pylori infection is
confirmed by the positive rapid urease test or 13C-breath test.

Exclusion Criteria:

- Patients with significant underlying disease including liver, cardiac, pulmonary, and
renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric
surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,
NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of
allergic reactions to any of the medications used in this protocol. Patients
previously treated with H. pylori eradication regimens or those unwilling to
participate in the study were also excluded.